4.2 Article

Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT)

Journal

NEUROMUSCULAR DISORDERS
Volume 25, Issue 12, Pages 937-944

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.nmd.2015.09.012

Keywords

Rating scale; Patient-reported outcome; Functional ability; Rasch analysis; Costs; Utilities

Funding

  1. GlaxoSmithKline [HO-11-794]
  2. European Commission [036825]
  3. Second Public Health Programme [2012 3307]
  4. AFM [16104]
  5. German Duchenne Parent Project aktion benni co
  6. Deutsche Gesellschaft fur Muskelkranke (DGM) e.V.
  7. Action Duchenne, a patient led charity
  8. Parent Project Muscular Dystrophy (PPMD)
  9. Medical Research Council as part of the MRC Centre for Neuromuscular Diseases [G1002274, 98482]
  10. MRC [MR/K000608/1, G1002274] Funding Source: UKRI
  11. Medical Research Council [MR/K000608/1, G1002274] Funding Source: researchfish
  12. National Institute for Health Research [NF-SI-0512-10036] Funding Source: researchfish

Ask authors/readers for more resources

The objective of this study was to describe the development and initial psychometric analysis of the UK English version of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT), a patient-reported outcome (PRO) scale designed to measure functional ability in patients with Duchenne muscular dystrophy (DMD). Item selection was made by neuromuscular specialists and a Rasch analysis was performed to understand the psychometric properties of the DMDSAT. Instrument scores were also linked to cost of illness and health-related quality of life data. The administered version, completed by 186 UK patient-caregivers pairs, included eight items in four domains: Arm function, Mobility, Transfers, and Ventilation status. These items together successfully operationalized functional ability in DMD, with excellent targeting and reliability (Person Separation Index: 0.95; Cronbach's alpha: 0.93), stable item locations, and good fit to the Rasch model (mean person/item fit residual: -0.211/-0.44, SD: 0.32/1.28). Estimated item difficulty was in excellent agreement with clinical opinion (Spearman's rho: 0.95) and instrument scores mapped well onto health economic outcomes. We show that the DMDSAT is a PRO instrument fit for purpose to measure functional ability in ambulant and non-ambulant patients with DMD. Rasch analysis augments clinical expertise in the development of robust rating scales. (C) 2015 The Authors. Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available